Available technologies 2017-03-17T12:51:37+00:00

Available technologies

Stem Cell Therapy Replacement for Retinal Ganglion Cells: Treatment for Glaucoma and Other Eye Diseases

Glaucoma is disease in the eye characterised by the progressive loss of retinal ganglion cells. Stem cell based therapeutics provide a method for restoration of neurons damaged by retinal disease. We have identified a population of neural stem cells in the adult human eye that can be isolated from donor retina. Stem cells can differentiate into retinal neurons in vitro and in vivo following transplantation into animal models of retinal degeneration.
More info →

Diagnosing Apoptosing Retinal Cells: Diagnostic for Glaucoma & Alzheimers Disease

DARC: the Diagnosis of Apoptosing Retinal Cells is a new early stage diagnostic method for glaucoma, Alzheimer's and other neurodegenerative diseases. DARC can also be used as an end point marker for the evaluation of neuroprotective drugs.
More info →

Dry Eye Diagnosis and Monitoring Software

Clinicians at Moorfields Eye Hospital, the leading provider of eye health services in Europe have developed the first medical device which is able to quantify dry eye in a patient. The software quantifies the number, distribution and size of fluorescein staining allowing screening, diagnosis and monitoring of the dry eye and other eye diseases.
More info →

Drug Delivery System for Crossing the Blood Brain or Blood Retinal Barrier (UDDS)

The blood retinal barrier (BRB), and the blood brain barrier (BBB), represent a significant impediment to drug delivery to the eye and the brain, respectively. This lack of drug penetration has resulted in diseases, such as Age-related Macular Degeneration (AMD), Alzheimer's Disease and Stroke being extremely difficult to address.

Although therapies to eye disease such as AMD already exist, they are delivered by intraocular injections with high risk of side effects related to the administration, the most significant being retinal detachment. The current challenge is to develop drug-delivery systems that ensure transitions across these barriers in a safe and effective manner.
More info →

Early Diagnosis of Alzheimer’s Disease

Alzheimer Disease (AD) is the most common neurodegenerative disorder affecting half of all the people above 80 years of age. The available diagnostic methods are expensive and are not available to all patients. An easily detectable biomarker that could be used for diagnosis and monitoring of AD is needed. Researchers at UCL Institute of Ophthalmology demonstrated that measuring drusen deposits in the periphery of the eye can be used as diagnostic method for AD.
More info →

Ultra-Fast Fluidic Analysis

A research group at UCL have developed a new microfluidic-based method which can be used in combination with either chemical or optical heating-based denaturation to measure protein stability curves and calculate affinity constants from nanolitre sample volumes.

Measurement times are significantly reduced from standard methods and envisaged applications range from high-throughput drug discovery to healthcare diagnostics and pathogen detection.
More info →

Passive Wireless Detection System

A team of researchers at UCL's Department of Electronic and Electrical Engineering, have developed a method for detection and tracking using existing wireless signals (WiFi) present in the everyday environment.
More info →

OpSAFE

OpSAFE is a medical device that enables touch free use of OsiriX MD image viewer for medical images.
More info →

Novel Percutaneous Heart Valve

A novel design of artificial aortic valve for transcatheter implantation.
More info →

Compliment Factor H Related 5 protein (CFHR5) and kidney disease

We have demonstrated that an abnormality of the protein Complement Factor H Related 5 (CFHR5) leads to a disposition of complement C3 and kidney failure. we have invented an efficient test for this genetic abnormality and have used it to screen a population. We have also invented an ELISA assay to measure the circulating CFHR5 protein levels in humans. We believe this will be useful in diagnosis and assessment of patients with a variety of diseases including SLE, immune complex glomerulonephritis and perhaps age-related macular degeneration. We have also proposed a role for CFHR5 protein (or agents mimicking its action) in the treatment of these diseases and are currently testing this experimentally.
More info →
Loading...